Literature DB >> 230695

Lipid metabolic studies in oophorectomized women. Effects of three different progestogens.

G Silfverstolpe, A Gustafson, G Samsioe, A Svanborg.   

Abstract

Ten oophorectomized women (ranging in age from 27 to 45 years, having a mean age of 34.5 years with a standard deviation of 5.3) were given three different progestogens (norgestrel, norethisterone and medroxyprogesterone) in treatment periods of 3 weeks' duration immediately preceded by 3 weeks "wash out" periods. Venous blood samples were drawn before and after each treatment period. Free and total cholesterol, triglycerides and phospholipids were determined in the three lipoprotein fractions: Very low density lipoproteins (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL). Individual phosphatides were determined after thin layer chromatography. In addition, the relative fatty acid composition of serum lecithin and cholesterol esters were assessed by gas-liquid-chromatography. Both norethisterone and norgestrel caused a decrease in alpha-lipoprotein cholesterol. The relative fatty acid composition of serum lecithin revealed an increase of biochemical pathway 1 for liver lecithin synthesis on norgestrel and norethisterone but no major changes on medroxyprogesterone. With norgestrel an increase in serum-lysolecithin concomitant with a decrease in lecithin was observed, while the two other progestogens did not induce any significant changes. From the present data it is suggested that the 19-norethisterone derivatives, norethisterone and especially norgestrel, have androgen-like influences on lipid metabolism. Medroxyprogesterone, being a 17-alpha-hydroxyprogesterone, caused less changes and consequently less disturbance of lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230695     DOI: 10.3109/00016347909157235

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand Suppl        ISSN: 0300-8835


  9 in total

Review 1.  A risk-benefit assessment of estrogen therapy in postmenopausal women.

Authors:  M P Cust; K F Gangar; T C Hillard; M I Whitehead
Journal:  Drug Saf       Date:  1990 Sep-Oct       Impact factor: 5.606

2.  Facts about injectable contraceptives: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

Review 3.  Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

Authors:  A K Mantel-Teeuwisse; J M Kloosterman; A H Maitland-van der Zee; O H Klungel; A J Porsius; A de Boer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

5.  Effects of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women.

Authors:  B M Wolfe; M W Huff
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy.

Authors:  A Kauppila; S Kivinen; P Leinonen; R Tuimala; R Vihko; P Ylöstalo
Journal:  Arch Gynecol       Date:  1983

7.  Lipid and carbohydrate metabolism studies in oophorectomized women: effects produced by the addition of norethisterone acetate to two estrogen preparations.

Authors:  G Silfverstolpe; A Gustafson; G Samsioe; A Svanborg
Journal:  Arch Gynecol       Date:  1982

Review 8.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

9.  Effect of large-dose progesterone on plasma levels of lipids, lipoproteins and apolipoproteins in males.

Authors:  J J Chen; F S Berlin; S Margolis
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.